|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 10/31/14 MusclePharm Corp 10-Q/A 6/30/14 92:9M Toppan Merrill/FA |
Document/Exhibit Description Pages Size
1: 10-Q/A Amendment to Quarterly Report HTML 356K
2: EX-31.1 Certification -- §302 - SOA'02 HTML 31K
3: EX-31.2 Certification -- §302 - SOA'02 HTML 31K
4: EX-32.1 Certification -- §906 - SOA'02 HTML 26K
5: EX-32.2 Certification -- §906 - SOA'02 HTML 26K
62: R1 Document And Entity Information HTML 49K
49: R2 Consolidated Balance Sheets HTML 137K
60: R3 Consolidated Balance Sheets [Parenthetical] HTML 49K
64: R4 Consolidated Statements of Operations HTML 111K
84: R5 Consolidated Statements of Cash Flows HTML 157K
51: R6 Nature of Operations and Basis of Presentation HTML 32K
59: R7 Summary of Significant Accounting Policies HTML 70K
44: R8 Composition of Certain Financial Statement HTML 154K
Captions
34: R9 Concentrations HTML 68K
85: R10 Financial Instruments HTML 46K
66: R11 Debt HTML 54K
65: R12 Derivative Liabilities HTML 35K
71: R13 Restricted Stock Units HTML 36K
72: R14 Stockholders' Equity HTML 114K
69: R15 Commitments, Contingencies and Other Matters HTML 71K
73: R16 Defined Contribution Plan HTML 30K
61: R17 Related Party Transactions HTML 35K
63: R18 Endorsement Agreement HTML 29K
68: R19 Biozone Acquisition HTML 122K
92: R20 Intangible Assets HTML 66K
80: R21 Restatement of June 30, 2014 Unaudited HTML 118K
Consolidated Financial Statements
55: R22 Subsequent Events HTML 31K
67: R23 Summary of Significant Accounting Policies HTML 139K
(Policies)
57: R24 Concentrations (Tables) HTML 68K
25: R25 Composition of Certain Financial Statement HTML 164K
Captions (Tables)
81: R26 Financial Instruments (Tables) HTML 40K
88: R27 Debt (Tables) HTML 51K
39: R28 Derivative Liabilities (Tables) HTML 32K
38: R29 Stockholders' Equity (Tables) HTML 108K
42: R30 Committments, Contingencies and Other Matters HTML 65K
(Tables)
43: R31 Biozone Acquisition (Tables) HTML 116K
45: R32 Intangible Assets (Tables) HTML 67K
19: R33 Restatement of June 30, 2014 Unaudited HTML 113K
Consolidated Financial Statements (Tables)
78: R34 Composition of Certain Financial Statement HTML 35K
Captions (Details)
53: R35 Composition of Certain Financial Statement HTML 39K
Captions (Details 1)
56: R36 Composition of Certain Financial Statement HTML 55K
Captions (Details 2)
29: R37 Composition of Certain Financial Statement HTML 33K
Captions (Details 3)
91: R38 Composition of Certain Financial Statement HTML 32K
Captions (Details 5)
12: R39 Composition of Certain Financial Statement HTML 51K
Captions (Details 4)
46: R40 Composition of Certain Financial Statement HTML 47K
Captions (Details 6)
83: R41 Composition of Certain Financial Statement HTML 34K
Captions (Details 7)
27: R42 Composition of Certain Financial Statement HTML 35K
Captions (Details 8)
37: R43 Composition of Certain Financial Statement HTML 28K
Captions (Details Textual)
41: R44 Concentrations (Details) HTML 33K
50: R45 Concentrations (Details 1) HTML 33K
18: R46 Concentrations (Details 2) HTML 30K
33: R47 Financial Instruments (Details) HTML 41K
14: R48 Financial Instruments (Details Textual) HTML 26K
82: R49 Debt (Details) HTML 44K
26: R50 Debt (Details 1) HTML 30K
79: R51 Debt (Details 2) HTML 30K
30: R52 Debt (Details Textual) HTML 47K
47: R53 Derivative Liabilities (Details) HTML 34K
13: R54 Derivative Liabilities (Details Textual) HTML 30K
17: R55 Restricted Stock Units (Details Textual) HTML 71K
40: R56 Stockholders' Equity (Details) HTML 55K
21: R57 Stockholders' Equity (Details 1) HTML 30K
86: R58 Stockholders' Equity (Details 2) HTML 48K
52: R59 Stockholders' Equity (Details 3) HTML 53K
70: R60 Stockholders' Equity (Details Textual) HTML 41K
32: R61 Commitments, Contingencies and Other Matters HTML 45K
(Details)
35: R62 Commitments, Contingencies and Other Matters HTML 41K
(Details 1)
77: R63 Commitments, Contingencies and Other Matters HTML 40K
(Details 2)
75: R64 Commitments, Contingencies and Other Matters HTML 53K
(Details Textual)
54: R65 Defined Contribution Plan (Details Textual) HTML 29K
76: R66 Related Party Transactions (Details Textual) HTML 51K
31: R67 Endorsement Agreement (Details Textual) HTML 28K
58: R68 Biozone Acquisition (Details) HTML 63K
87: R69 Biozone Acquisition (Details 1) HTML 32K
16: R70 Biozone Acquisition (Details 2) HTML 42K
24: R71 Biozone Acquisition (Details Textual) HTML 36K
48: R72 Intangible Assets (Details) HTML 43K
20: R73 Intangible Assets (Details 1) HTML 41K
90: R74 Intangible Assets (Details Textual) HTML 28K
28: R75 Restatement of June 30, 2014 Unaudited HTML 113K
Consolidated Financial Statements (Details)
22: R76 Restatement of June 30, 2014 Unaudited HTML 32K
Consolidated Financial Statements (Details
Textual)
23: R77 Subsequent Events (Details Textual) HTML 39K
89: XML IDEA XML File -- Filing Summary XML 136K
15: EXCEL IDEA Workbook of Financial Reports XLSX 190K
36: EXCEL IDEA Workbook of Financial Reports (.xls) XLS 1.52M
6: EX-101.INS XBRL Instance -- mslp-20140630 XML 2.06M
8: EX-101.CAL XBRL Calculations -- mslp-20140630_cal XML 220K
9: EX-101.DEF XBRL Definitions -- mslp-20140630_def XML 1.09M
10: EX-101.LAB XBRL Labels -- mslp-20140630_lab XML 1.27M
11: EX-101.PRE XBRL Presentations -- mslp-20140630_pre XML 1.22M
7: EX-101.SCH XBRL Schema -- mslp-20140630 XSD 230K
74: ZIP XBRL Zipped Folder -- 0001144204-14-064325-xbrl Zip 191K
Exhibit 32.1
Section 1350 CERTIFICATION
In connection with this Quarterly Report of MusclePharm Corporation (the “Company”), on Form 10-Q/A for the quarter ended June 30, 2014, as filed with the U.S. Securities and Exchange Commission on the date hereof (the “Report”), I, Brad J. Pyatt, Principal Executive Officer of the Company, certify pursuant to 18 U.S.C. Section. 1350, as adopted pursuant to Section. 906 of the Sarbanes-Oxley Act of 2002, that:
| (1) | The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and |
| (2) | The information contained in the Report, fairly presents, in all material respects, the financial condition and results of operations of the Company. |
| Date: October 31, 2014 | By: | /s/ Brad J. Pyatt |
| Brad J. Pyatt | ||
| Principal Executive Officer |
C:
| This ‘10-Q/A’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 10/31/14 | 10-K/A, 8-K | ||
| For Period end: | 6/30/14 | 10-Q | ||
| List all Filings | ||||